Ngm Biopharmaceuticals, Inc. (NGM) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Ngm Biopharmaceuticals, Inc. faces a significant business risk with potential stockholder litigation that may impede or entirely halt the progression of its Offer and Merger. The company is likely to bear additional costs tied to defending or resolving any forthcoming stockholder lawsuits, which may unfavorably affect its financial health and operational results. The requisite Legal Restraints condition delineated in the Merger Agreement adds to the uncertainty, as legal injunctions or prohibitions by government entities could severely disrupt or block the Merger. Should litigants obtain such relief, it could derail Ngm Biopharmaceuticals’ strategic plans, jeopardizing the timely completion or occurrence of the Offer and Merger.
Overall, Wall Street has a Hold consensus rating on NGM stock based on 4 Holds.
To learn more about Ngm Biopharmaceuticals, Inc.’s risk factors, click here.
